ПАТОГЕНЕТИЧЕСКИЕ АСПЕКТЫ РАКОВОЙ АНОРЕКСИИ
Аннотация
Анорексия и ограниченное питание - это физиологическая реакция организма на развитие рака (то есть активация иммунной системы, повышенное потребление энергии...). Изначально считается, что все эти изменения помогают организму бороться с ростом опухоли. В этом контексте эффективность лечения анорексии связана с несколькими механизмами. Во-первых, организм пациента не активирован и не находится в поисках пищи и, таким образом, экономит энергию, это также снижает затраты тепла, которые могут возникнуть из-за повышенной конвекции. Сохраненная температура в этом случае используется организмом для борьбы с быстрым ростом рака. Во-вторых, уменьшение количества пищи во время болезни также уменьшает потребление питательных веществ, необходимых раковым клеткам, а также снижает потребление энергии, необходимой для пищеварения. Этот эффект начальной стадии анорексии подтверждается классическим исследованием, в котором принудительное кормление инфицированных подопытных мышей приводило к увеличению уровня смертности (1). Тем не менее, несмотря на преимущества, которые приносит анорексия в начале заболевания, длительная анорексия ставит под угрозу защитные функции организма и затрудняет выздоровление.
Библиографические ссылки
Murray MJ, Murray AB. Anorexia of infection as a mechanism of host defense. Am J Clin Nutr 1979; 32:593-596.
Bernstein IL. Taste aversion learning: a contemporary perspective. Nutrition 1999; 15:229-234.
Sutton LM, Demark-Wahnefried W, Clipp EC. Management of terminal cancer in elderly patients. Lancet Oncol 2003; 4:149-157.
DeWys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69:491-497.
Pirovano M, Maltoni M, Nanni O, et al. A new palliative score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manage 1999; 17:231-239.
Maltoni M, Nanni O, Pirovano M, et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage 1999; 17:240-247.
Donnelly S, Walsh D. The symptoms of advanced cancer. Semin Oncol 1995; 22 (suppl. 3): 67-72.
Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2:862-871.
Walsh D, Rybicki L, Nelson KA, et al. Symptoms and prognosis in advanced cancer. Support Care Cancer 2002; 10:385-388.
Maltoni M, Pirovano M, Scarpi E, et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer 1995; 75:2613-2622.
Rakhimov M. Nodir, Khudayberdiyeva A. Shohista, Oripova R. Mehriniso, Shakhanova Sh. Shakhnoza. Practical recommendations for Nutritional support for cervical cancer // Journal of Biomedicine and Practice. 2023, vol. 8, issue 2, pp.224-230
Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Cancer: disease and nutrition are key determinants of patients' quality of life. Support Care Cancer 2004; 12:246-252.
Laviano A, Meguid MM, Rossi Fanelli F. Cancer anorexia: clinical implications, pathogenesis and therapeutic strategies. Lancet Oncol 2003; 4:686-694.
Rossi Fanelli F, Cangiano C, Ceci F, et al. Plasma tryptophan and anorexia in human cancer. Eur J Cancer Clin Oncol 1986; 22:89-95.
Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000; 404:661-671.
Shakhanova Sh. Shakhnoza, Rakhimov M. Nodir. Aspects of sarcopenia syndrome in oncological practice: diagnosis and treatment (literature review) // Journal of Biomedicine and Practice. 2023, vol. 8, issue 3, pp. 406-417
Chance WT, Sheriff S, Moore J, et al. Reciprocal changes in hypothalamic receptor binding and circulating leptin in anorectic tumor-bearing rats. Brain Res 1998; 803:27-33.
Simons JP, Schols AM, Campfield LA, et al. Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci 1997; 93:273-277.
Bing C, Taylor S, Tisdale MJ, et al. Cachexia in MAC 16 adeno-carcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic NPY. J Neurochem 2001; 79:1004-1012.
Mantovani G, Maccio A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000; 78:554-561.
Inui A, Asakawa A, Bowers CY, et al. Ghrelin, appetite and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J 2004; 18:439-456.
Laviano A, Meguid MM; Inui A, et al. Therapy Insight: cancer anorexia-cachexia sindrome - when all you can eat is yourself. Nat Clin Pract Oncol 2005; 2:158-165.
Kahler A, Zimmermann M, Langhans W. Suppression of hepatic fatty acid oxidation and food intake in men. Nutrition 1999; 15:819-828.
Loftus TM, Jaworsky DE, Frehywot GL, et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000; 288:2379-2381.
Peluso G, Nicolai R, Reda E, et al. Cancer and anticancer therapy-induced modification on metabolism mediated by carnitine system. J Cell Physiol 2000; 182:339-350.
Makarenko IG, Meguid MM, Gatto L, et al.. Decreased NPY innervation of the hypothalamic nuclei in rats with cancer anorexia. Brain Res 2003; 961:100-108.
Marks DL, Ling N, Cone RD. Role of central melanocortin system in cachexia. Cancer Res 2001; 61:1432-1438.
Wisse BE, Frayo RS, Schwartz MW, et al. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001; 142:3292-3301.
Plata-Salaman CR. Anorexia during acute and chronic disease. Nutrition 1996; 12:69-78.
Opara EI, Laviano A, Meguid MM, et al. Correlation between food intake and CSF IL-1 in anorectic tumor bearing rats. NeuroReport 1995; 6:750-752.
Laviano A, Gleason JR, Meguid MM, et al. Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. J Investig Med 2000: 48:40-48.
Torelli GF, Meguid MM, Moldawer LL, et al. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol 1999; 277:R850-R855.
Wang W, Lonnroth C, Svanberg E, et al. Cytokine and COX-2 protein in brain areas of tumor-bearing mice with prostanoid-related anorexia. Cancer Res 2001, 61:4707-4715.
Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 1999; 59:4493-4501.
Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfluramine. Science 2002, 297:609-611.
Shintani F, Kanba S, Nakaki T, et al. Interleukin-1beta augments release of norepinephrine, dopamine and serotonin in the rat anterior hypothalamus. J Neurosci 1993; 13:3574-3581.
Blaha V, Yang ZJ, Meguid MM, et al. Ventromedial nucleus of hypothalamus is related to the development of cancer-induced anorexia: in vivo microdialysis study. Acta Medica (Hradec Kralove) 1998; 41:3-11.
Cangiano C, Cascino A, Ceci F, et al. Plasma and CSF tryptophan in cancer anorexia. J Neural Transm (Gen Sect) 1990; 81:225-233.
Ravasco P. Aspects of taste and compliance in patients with cancer. Eur J Oncol Nurs 2005; 9 (suppl. 2):S84-S91.
Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 2002; 52:72-91.
Shakhanova Sh. Shakhnoza, Rakhimov M. Nodir. Aspects of sarcopenia syndrome in oncological practice: diagnosis and treatment (literature review) // Journal of Biomedicine and Practice. 2023, vol. 8, issue 3, pp. 406-417
Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia treatment. J Clin Oncol 1999; 17:3299-3306.
